By combining Dario's multi-condition engagement offering with Beluga's physician-led, 50-state clinical network, the monitoring, detection and treatment of members can happen within one platform. Coaching, AI-driven triage and, with Beluga, clinical treatment across hypertension, diabetes, obesity, behavioral health and musculoskeletal care, are now all integrated in a single, easy-to-manage vendor relationship. When a member's biometric signal deteriorates, the platform automatically routes patients directly to a prescribing clinician – completing the loop from initial detection all the way through treatment. This whole approach effects an entire category advancement.

This distinguishes Dario from pure engagement vendors. Because chronic conditions can compound over time, Dario's platform grows with each member, rather than handing them off. Dario's solution performance is evidence-based: in a study published in JMIR, Dario users had 23% lower hospitalization rates and 26% lower total charges than matched patients receiving usual care. For health plans, the Agreement positions Dario as a quality and revenue performance partner that delivers impact based on where plans are economically incentivized: just a half-star CMS Star Rating gain can be worth roughly $500 per member, and gaps in accurate risk-adjustment documentation can cost more than $1,000 per member per year. Beluga's white-label medical infrastructure addresses this without Dario building or operating a provider network, thereby expanding contract value per client at high margin.

The Agreement also unlocks new markets. Dario already serves 12 health plans, 3 of them national – a built-in channel to deliver the joint solution to members whose plans adopt it. Beyond existing commercial and Medicare Advantage clients, the integrated architecture opens new growth segments such as state Medicaid programs, federal Rural Health Transformation initiatives and direct health-system partnerships – buyers who increasingly require proof of clinical action, not just engagement. For health systems, that proof is economic, (i.e., keeping complex, comorbid patients and their downstream revenue in network while reducing readmissions that carry direct CMS penalties). For employers, the identification and treatment of chronic-conditions before escalation mitigates risk and limits expensive outcomes before they can happen.